Cargando…

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia

BACKGROUND: Hospital-acquired pneumonia (HAP) is the most common health care-associated infection contributing to death. Studies have indicated that there may be differences in the causative pathogens and outcomes of ventilator-associated pneumonia (VAP) and non-ventilator-associated pneumonia (NV-H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubinstein, Ethan, Stryjewski, Martin E, Barriere, Steven L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035308/ https://www.ncbi.nlm.nih.gov/pubmed/24876786 http://dx.doi.org/10.2147/IDR.S25930

Ejemplares similares

Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates
por: Smart, Jennifer I., et al.
Publicado: (2016)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus
por: Corey, G. Ralph, et al.
Publicado: (2015)

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2009)

Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure
por: Torres, A., et al.
Publicado: (2014)

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials
por: Niederman, Michael S., et al.
Publicado: (2019)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies
por: Barriere, Steven L, et al.
Publicado: (2014)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Bacteremic nosocomial pneumonia cases from the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2010)

Determinants of Mortality for Ventilated Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
por: Motowski, Hayley, et al.
Publicado: (2023)

Viruses are prevalent in non-ventilated hospital-acquired pneumonia
por: Shorr, Andrew F., et al.
Publicado: (2017)

Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?
por: Vallecoccia, Maria Sole, et al.
Publicado: (2020)

Aerosolized antibiotics in the treatment of hospital-acquired pneumonia/ventilator-associated pneumonia
por: Jung, Yun Jung, et al.
Publicado: (2022)

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
por: Hooper, Candace Y, et al.
Publicado: (2012)

Late ventilator-associated pneumonia: analysis of baseline characteristics and clinical outcomes in the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2010)

Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia
por: Torres, Antoni, et al.
Publicado: (2018)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Reply to Tarchini
por: Rubinstein, Ethan, et al.
Publicado: (2011)

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study
por: Stryjewski, Martin E, et al.
Publicado: (2014)

What is new in non-ventilated ICU-acquired pneumonia?
por: Saied, Wafa Ibn, et al.
Publicado: (2020)

Utilization Trends and Predictors of Non-invasive and Invasive Ventilation During Hospitalization Due to Community-Acquired Pneumonia
por: Shah, Harshil, et al.
Publicado: (2021)

Performance and impact of a multiplex PCR in ICU patients with ventilator-associated pneumonia or ventilated hospital-acquired pneumonia
por: Peiffer-Smadja, Nathan, et al.
Publicado: (2020)

Dental and Microbiological Risk Factors for Hospital-Acquired Pneumonia in Non-Ventilated Older Patients
por: Ewan, Victoria C., et al.
Publicado: (2015)

Clinical Efficacy of Cefoperazone-Sulbactam versus Piperacillin-Tazobactam in the Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
por: Chen, Chia-Hung, et al.
Publicado: (2021)

1476. Objective Surveillance Definitions for Hospital-Acquired Pneumonia in Non-Ventilated Patients
por: Ji, Wenjing, et al.
Publicado: (2018)

93. Enhanced Oral Care as Prevention for Non-ventilator Hospital Acquired Pneumonia
por: Giuliano, Karen K, et al.
Publicado: (2020)

The current pathogens and treatment of hospital-acquired pneumonia/ventilator-associated pneumonia in medical intensive care units
por: Chang, Y, et al.
Publicado: (2015)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

Prevention of hospital-acquired pneumonia in non-ventilated adult patients: a narrative review
por: Pássaro, Leonor, et al.
Publicado: (2016)

Incidence and outcomes of hospitalization for community-acquired, ventilator-associated and non-ventilator hospital-acquired pneumonias in patients with type 2 diabetes mellitus in Spain
por: Lopez-de-Andres, Ana, et al.
Publicado: (2020)

Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
por: Naik, Jaesh, et al.
Publicado: (2021)

Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial
por: Stergiopoulos, Stella, et al.
Publicado: (2018)

Correction: Incidence and outcomes of hospitalization for community-acquired, Ventilator-associated and non-ventilator Hospital-acquired pneumonias in patients with type 2 diabetes mellitus in Spain
Publicado: (2020)

Narrative Review of the Epidemiology of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Gulf Cooperation Council Countries
por: Abdalla, Jehad S., et al.
Publicado: (2023)

Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients
por: Ferrer, Miquel, et al.
Publicado: (2018)

1472. Antibiotic De-escalation Compared with Continued Empirical Treatment in Non-Ventilated Hospital-Acquired Pneumonia
por: Alnaimi, Shaikha, et al.
Publicado: (2018)

Risk factors for infection with multidrug-resistant bacteria in non-ventilated patients with hospital-acquired pneumonia,
por: Seligman, Renato, et al.
Publicado: (2013)

Non-invasive pressure support ventilation in severe community-acquired pneumonia
por: Jolliet, Philippe, et al.
Publicado: (2001)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k2j94pc3m7ehqs07ljnnh2b61b